{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:02:10Z","timestamp":1777633330022,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"\n Background<\/jats:title>\n \n Details regarding kidney-protective mechanisms of sodium-glucose cotransporter 2 (SGLT2) inhibitors remain unclear. High kidney resistive index (RI), evaluated by Doppler ultrasonography, and low T\n 2<\/jats:sub>\n * value, evaluated by blood oxygenation level-dependent (BOLD) magnetic resonance imaging (MRI) are risk factors for chronic kidney disease progression. In our previous study, canagliflozin (Cana) improved kidney oxygenation. In this\n post-hoc<\/jats:italic>\n analysis, the effects of Cana on RI, as well as the correlation between changes in RI and T\n 2<\/jats:sub>\n * values, were evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Thirteen patients with type 2 diabetes (T2D) were analyzed. RI was determined at screening and on Day 5 (D5) following administration of Cana, while BOLD MRI was performed on D0, D1 (administration day), and D5. Cortical T\n 2<\/jats:sub>\n * values were evaluated using twelve-layer concentric object (TLCO) and region of interest (ROI) methods. Changes in RI and T\n 2<\/jats:sub>\n * values from D0 to D1 or D5 are expressed as \u0394RI, \u0394T\n 2<\/jats:sub>\n * (D1\u2013D0), and \u0394 T\n 2<\/jats:sub>\n * (D5\u2013D0), respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Cana significantly decreased RI, while ROI findings showed increased T\n 2<\/jats:sub>\n * (D0: 54.5 [50.8\u201355.5] vs D1: 56.2 [52.7\u201356.4],\n p<\/jats:italic>\n =\u00a00.003,\n r<\/jats:italic>\n \u00a0=\u00a00.77; D0 vs D5: 54.5 [53.0\u201357.2],\n p<\/jats:italic>\n \u00a0=\u00a00.080,\n r<\/jats:italic>\n \u00a0=\u00a00.49). A significant negative correlation between \u0394RI and \u0394T\n 2<\/jats:sub>\n * (D1\u2013D0) was shown by both TLCO (\n \u03c1<\/jats:italic>\n =\u00a0-0.621,\n p<\/jats:italic>\n \u00a0=\u00a00.024) and ROI (\n \u03c1<\/jats:italic>\n \u00a0=\u00a0-0.557,\n p<\/jats:italic>\n \u00a0=\u00a00.048).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Short-term Cana treatment improved RI and kidney oxygenation in patients with T2D. The inverse correlation found between changes in RI and T\n 2<\/jats:sub>\n * values suggest a mechanistic link between hemodynamic changes and improved oxygenation by SGLT2 inhibitors.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcdhc.2026.1733806","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:34:10Z","timestamp":1777437250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of canagliflozin on kidney resistive index and oxygenation in patients with type 2 diabetes: findings obtained with ultrasonography and blood oxygenation level-dependent MRI"],"prefix":"10.3389","volume":"7","author":[{"given":"Hideki","family":"Uedono","sequence":"first","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Kindai University Nara Hospital","place":["Nara, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Saitama Medical University","place":["Saitama, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Machiba","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyuki","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Saitama Medical University","place":["Saitama, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]},{"name":"Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-00567-x","article-title":"Renal intraparenchymal resistive index: the ultrasonographic answer to many clinical questions","volume":"32","author":"Di Nicol\u00f2","year":"2019","journal-title":"J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2148-y","article-title":"Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes","volume":"54","author":"Bruno","year":"2011","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.455","article-title":"Assessment of renal resistance index after captopril test by Doppler in essential and renovascular hypertension","volume":"48","author":"Veglio","year":"1995","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.34","article-title":"The renal arterial resistance index: a marker of renal function with an independent and incremental role in predicting heart failure progression","volume":"16","author":"Ciccone","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.261","article-title":"Intrarenal hemodynamic abnormalities in diabetic nephropathy measured by duplex Doppler sonography","volume":"51","author":"Ishimura","year":"1997","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.10.020","article-title":"Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease","volume":"93","author":"Pruijm","year":"2018","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy324","article-title":"Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease","volume":"35","author":"Sugiyama","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100895","article-title":"Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomized, double-blind, placebo-controlled crossover trial","volume":"37","author":"Laursen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2021.101274","article-title":"Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function","volume":"47","author":"Zhou","year":"2021","journal-title":"Diabetes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05876-w","article-title":"Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomized trial","volume":"66","author":"Gullaksen","year":"2023","journal-title":"Diabetologia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1451671","article-title":"Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes","volume":"15","author":"Mori","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0234-0","article-title":"Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"32","author":"Iijima","year":"2015","journal-title":"Adv Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"22129","DOI":"10.1038\/s41598-021-01147-z","article-title":"Comparison of multiparametric magnetic resonance imaging sequences with laboratory parameters for prognosticating renal function in chronic kidney disease","volume":"11","author":"Inoue","year":"2021","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4561309","DOI":"10.1016\/j.artres.2017.10.095","article-title":"Ultrasonographic characterization of the db\/db mouse: an animal model of metabolic abnormalities","volume":"2018","author":"Faita","year":"2018","journal-title":"J Diabetes Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1323-3","article-title":"Renal resistive index: not only kidney","volume":"21","author":"Di Nicol\u00f2","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000090605","article-title":"Renal Doppler sonography--update in clinical nephrology","volume":"103","author":"Krumme","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl484","article-title":"Do ultrasound renal resistance indices reflect systemic rather than renal vascular damage in chronic kidney disease","volume":"22","author":"Heine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04183","article-title":"Renal resistive index: a case of mistaken identity","volume":"64","author":"O'Neill","year":"2014","journal-title":"Hypertension"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2008.07.003","article-title":"Measurement of the intrarenal arterial resistance index for the identification and prediction of diabetic nephropathy","volume":"19","author":"Masulli","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000446965","article-title":"Metabolic and hormonal determinants of glomerular filtration rate and renal hemodynamics in severely obese individuals","volume":"9","author":"Vitolo","year":"2016","journal-title":"Obes Facts"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/oby.22355","article-title":"Renal resistive index predicts post-bariatric surgery renal outcome in nondiabetic individuals with severe obesity","volume":"27","author":"Solini","year":"2019","journal-title":"Obes (Silver Spring)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae370","article-title":"Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications","volume":"18","author":"Le\u00f3n-Jim\u00e9nez","year":"2025","journal-title":"Clin Kidney J"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1733806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:34:20Z","timestamp":1777437260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1733806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":32,"alternative-id":["10.3389\/fcdhc.2026.1733806"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2026.1733806","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1733806"}}